Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
December 9, 2016 2:15 PM EST
Mizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).
"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new... More
December 9, 2016 6:29 AM EST
BMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
December 8, 2016 3:03 PM EST
(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
